

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

CLARK et al

Appln. No. 10/020,436

Filed: December 18, 2001

Confirmation No. 1671

Atty. Ref.: 179-54

T.C. / Art Unit: 1639

Examiner: TD. Wessendorf

For: A METHOD FOR MAPPING THE ACTIVE SITES BOUND BY ENZYMES THAT
COVALENTLY MODIFY SUBSTRATE MOLECULES

* * * * *

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97(c)

June 7, 2004

Mail Stop Amendment

U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Attached is a Form PTO-1449 listing the enclosed documents.

The Official Fee required under 37 CFR § 1.97(c) is filed herewith. Should that fee be missing or inadequate, please charge the deficiency to our Deposit Account No. 14-1140 Matter No. 179-54 for which purpose this paper is submitted in duplicate.

This Information Disclosure Statement (IDS) is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under 37 CFR § 1.97(f), to enable Applicants to comply fully. In particular, if any of the listed documents are missing or incomplete, please contact the undersigned who will provide another copy.

As provided by 37 CFR §§ 1.97(g) and (h), no inference should be made that this information and the listed references are prior art merely because they have been submitted for consideration. Furthermore, no representation is being made that a search has been conducted or that this statement encompasses all possible material information.

This Page Blank (uspto)

CLARK et al. - Appln. No. 10/020,436

Consideration of the foregoing and enclosures, as well as the return of a copy of the Form PTO-1449 with the Examiner's initials per M.P.E.P. § 609, are earnestly solicited. The Examiner is invited to contact the undersigned if any further information is needed.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: 

Gary R. Yanigawa
Reg. No. 43,180

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

This Page Blank (uspto)

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

APPLN. NO.

179-54

10/020,436

APPLICANT

CLARK et al.

(Use several sheets if necessary)

FILING DATE

GROUP

December 18, 2001

1639

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

AR	Arpala et al. "Defective T cell receptor signaling and CD8 thymic selection in humans lacking Zap-70 kinase" Cell 76:947-958 (1994)
BR	Barker et al. "BRK tyrosine kinase expression in a high proportion of human breast carcinomas" Oncogene 15:799-805 (1997)
CR	Casnellie "Assay of protein kinases using peptides with basic residues for phosphocellulose binding" Meth. Enzymol. 200:115-120 (1991)
DR	Dente et al. "Modified phage peptide libraries as a tool to study specificity of phosphorylation and recognition of tyrosine containing peptides" J. Mol. Biol. 269:694-703 (1997)
ER	Elder et al. "Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase" Science 264:1596-1599 (1994)
FR	Hanks et al. "Protein kinase catalytic domain sequence database: Identification of conserved features of primary structure and classification of family members" Meth. Enzymol. 200:38-62 (1991)
GR	Kemp et al. "Pseudosubstrate-based peptide inhibitors" Meth. Enzymol. 201:287-304 (1991)
HR	Lee et al. "A protein kinase involved in the regulation of inflammatory cytokine biosynthesis" Nature 372:739-746 (1994)
IR	Lehtola et al. "Analysis of tyrosine kinase mRNAs including four FGF receptor mRNAs expressed in MCF-7 breast-cancer cells" Int. J. Cancer 50:598-603 (1992)
JR	Roifman "A mutation in zap-70 protein tyrosine kinase results in a selective immunodeficiency" J. Clin. Immunol. 15:52S-62S (1995)
KR	Songyang et al. "Use of an oriented peptide library to determine the optimal substrates of protein kinases" Curr. Biol. 4:973-982 (1994)
LR	Wardenburg et al. "Phosphorylation of SLP-76 by the ZAP-70 protein-tyrosine kinase is required for T-cell receptor function" J. Biol. Chem. 271:19641-19644 (1996)
MR	Wilson et al. "Crystal structure of p38 mitogen-activated protein kinase" J. Biol. Chem. 271:27696-27700 (1996)
NR	Xu et al. "Three-dimensional structure of the tyrosine kinase c-Src" Nature 385:595-602 (1997)
OR	Zhang et al. "Atomic structure of the MAP kinase ERK2 at 2.3 Å resolution" Nature 367:704-711 (1994)
PR	
QR	
RR	
SR	
TR	
UR	
VR	
WR	
XR	
YR	
ZR	

*Examiner

This Page Blank (uspto)